Ocrelizumab (Ocrevus) has become the first medicine to be licensed for primary progressive MS by the FDA (Food and Drug Administration), the American drug regulators. The FDA has also licensed ocrelizumab as a treatment for relapsing remitting MS.
NICE (National Institute for Health and Care Excellence) has approved Zinbryta (daclizumab) as a treatment for relapsing remitting multiple sclerosis on the NHS in England and Wales.
Two new reports published this week have highlighted the problems facing people trying to access neurological services in the UK
Researchers have discovered a protein that encourages the regrowth of myelin and may lead to new types of treatment for MS in the future
Canadian researchers have presented preliminary results from a clinical study which suggest that surgical treatment to unblock veins draining the brain and spinal cord is not effective in treating MS.